Sigrid (Sigrid Therapeutics AB), a consumer health company based in Stockholm, Sweden, recently raised USD$5 million in a funding round. Investors were not disclosed.
The latest capital injection brings the company’s total funding to approximately USD$27 million to date and is specifically earmarked to accelerate its U.S. commercial expansion efforts, where its Glucose Stabiliser product has seen over 3x revenue growth in the past year.